MedTrace Logo

Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas

NCT00274755 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2014-05-20

No results posted yet for this study

Summary

RATIONALE: Diagnostic procedures, such as magnetic resonance imaging (MRI) and magnetic resonance spectroscopic imaging (MRSI), (done before, during, and after treatment) may help doctors predict a patient's response to treatment and help plan the best treatment.

PURPOSE: This phase II trial is studying how well MRI and MRSI evaluate patients who are undergoing treatment for gliomas.

Conditions

Interventions

DRUG

chemotherapy

PROCEDURE

conventional surgery

PROCEDURE

magnetic resonance imaging

PROCEDURE

magnetic resonance spectroscopic imaging

RADIATION

radiation therapy

Sponsors & Collaborators

Principal Investigators

  • Sarah J. Nelson, PhD · University of California, San Francisco

Study Design

Purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-11-30
Primary Completion
2007-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00274755 on ClinicalTrials.gov